CTIS2023-506996-89-00招募中1 期
A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study - MK-3543-017
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 225
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •From a bomedemstat study sponsored by Imago Biosciences, Inc. (a subsidiary of Merck & Co., Inc.) or MSD, and established by the Sponsor as MK-3543-017 ready., Has received at least 6 months of treatment with bomedemstat in the IMG-7289-202/MK-3543-005 study, while safely tolerating bomedemstat, and receiving clinical benefit from its use in the estimation of the investigator, ET and PV participants from established feeder studies other than IMG-7289- 202/MK-3543-005 must have achieved confirmed hematologic remission, must be safely tolerating bomedemstat, and must be receiving clinical benefit from its use in the estimation of the investigator, Be able to initiate study intervention on Day 1 of the extension study (ie, not currently on a dose hold), Participant must be able to swallow oral medication and follow instructions for at-home dosing of bomedemstat
排除标准
- •Has received prohibited concomitant medications, Ongoing or planned participation in another investigational study, Has noncompliance in prior bomedemstat study receiving <90% of assigned doses excluding suspensions or holds as assigned by the investigator.
研究者
相似试验
进行中（未招募）
1 期
A study to test the safety and effects of Bomedemstat in patients with myeloproliferative neoplasmPatients with Myeloproliferative Neoplasms (MPNs)MedDRA version: 20.0Level: PTClassification code 10077465Term: Myeloproliferative neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002452-37-DEImago BioSciences Inc.80
进行中（未招募）
1 期
A study to test the safety and effects of Bomedemstat in patients with myeloproliferative neoplasm.EUCTR2021-002452-37-ITImago BioSciences, Inc80
进行中（未招募）
不适用
Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR) as Adjunctive Therapy in Subjects with Refractory Partial Epilepsy on up to Three Concomitant Antiepileptic MedicationsTreatment of seizures of partial origin in subjects with refractory epilepsyMedDRA version: 9.1Level: LLTClassification code 10015037Term: EpilepsyEUCTR2008-003334-19-BGSupernus Pharmaceuticals, Inc.360
招募中
1 期
A Study to evaluate the safety and tolerability of dapirolizumab pegol in study participants with systemic lupus erythematosusSystemic lupus erythematosusEUCTR2019-003409-83-ITCB Biopharma SR760
进行中（未招募）
1 期
An extension study to learn if Bimekizumab works and is safe over a long period in adults with Active Axial Spondyloarthritis.Axial SpondyloarthritisMedDRA version: 21.1Level: PTClassification code: 10071400Term: Axial spondyloarthritis Class: 100000004859CTIS2023-506527-28-00CB Biopharma691